Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 11 of 11 entries
Sorted by: Best Match Show Resources per page
Various techniques for the evaluation of anti arthritic activity in animal models.

Journal of advanced pharmaceutical technology & research

Pandey S.
PMID: 22247842
J Adv Pharm Technol Res. 2010 Apr;1(2):164-71.

Arthritis is an auto immune disorder characterized by pain, swelling and stiffness. Its prevalence depends upon age. It occurs more frequently in women than in men. It is an inflammation of synovial joint due to immuno mediated response. All...

Cite
Pandey S. Various techniques for the evaluation of anti arthritic activity in animal models. J Adv Pharm Technol Res. 2010;1(2):164-71
Pandey, S. (2010). Various techniques for the evaluation of anti arthritic activity in animal models. Journal of advanced pharmaceutical technology & research, 1(2), 164-71.
Pandey, Shivanand. "Various techniques for the evaluation of anti arthritic activity in animal models." Journal of advanced pharmaceutical technology & research vol. 1,2 (2010): 164-71.
Pandey S. Various techniques for the evaluation of anti arthritic activity in animal models. J Adv Pharm Technol Res. 2010 Apr;1(2):164-71. PMID: 22247842; PMCID: PMC3255441.
Copy Download .nbib Format: NLM
Effects of renal function on the urinary excretion and serum concentration of uric acid in patients with chronic kidney disease treated with febuxostat.

Journal of Nippon Medical School = Nippon Ika Daigaku zasshi

Yamada T, Kashiwagi T, Sakai Y.
PMID: 34840217
J Nippon Med Sch. 2021 Nov 26; doi: 10.1272/jnms.JNMS.2022_89-401. Epub 2021 Nov 26.

BACKGROUND: Febuxostat is recommended for patients with chronic kidney disease (CKD) associated with hyperuricemia to lower the serum uric acid (sUA) concentration. However, it remains uncertain how this drug affects correlations between several laboratory parameters regarding glomerular filtration and...

Cite
Yamada T, Kashiwagi T, Sakai Y. Effects of renal function on the urinary excretion and serum concentration of uric acid in patients with chronic kidney disease treated with febuxostat. J Nippon Med Sch. 2021;doi: 10.1272/jnms.JNMS.2022_89-401.
Yamada, T., Kashiwagi, T., & Sakai, Y. (2021). Effects of renal function on the urinary excretion and serum concentration of uric acid in patients with chronic kidney disease treated with febuxostat. Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, . https://doi.org/10.1272/jnms.JNMS.2022_89-401
Yamada, Takehisa, et al. "Effects of renal function on the urinary excretion and serum concentration of uric acid in patients with chronic kidney disease treated with febuxostat." Journal of Nippon Medical School = Nippon Ika Daigaku zasshi vol. (2021). doi: https://doi.org/10.1272/jnms.JNMS.2022_89-401
Yamada T, Kashiwagi T, Sakai Y. Effects of renal function on the urinary excretion and serum concentration of uric acid in patients with chronic kidney disease treated with febuxostat. J Nippon Med Sch. 2021 Nov 26; doi: 10.1272/jnms.JNMS.2022_89-401. Epub 2021 Nov 26. PMID: 34840217.
Copy Download .nbib Format: NLM
A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications.

European journal of pharmacology

Song D, Zhao X, Wang F, Wang G.
PMID: 34216576
Eur J Pharmacol. 2021 Sep 15;907:174291. doi: 10.1016/j.ejphar.2021.174291. Epub 2021 Jul 01.

Hyperuricemia is a common metabolic condition, cause by increased levels of serum urate (SUA). Reduced excretion of uric acid is reported as the key factor of primary hyperuricemia, accounting for approximately 90% of the cases. Urate transporter 1 (URAT1)...

Cite
Song D, Zhao X, Wang F, et al. A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications. Eur J Pharmacol. 2021;907:174291doi: 10.1016/j.ejphar.2021.174291.
Song, D., Zhao, X., Wang, F., & Wang, G. (2021). A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications. European journal of pharmacology, 907174291. https://doi.org/10.1016/j.ejphar.2021.174291
Song, Danni, et al. "A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications." European journal of pharmacology vol. 907 (2021): 174291. doi: https://doi.org/10.1016/j.ejphar.2021.174291
Song D, Zhao X, Wang F, Wang G. A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications. Eur J Pharmacol. 2021 Sep 15;907:174291. doi: 10.1016/j.ejphar.2021.174291. Epub 2021 Jul 01. PMID: 34216576.
Copy Download .nbib Format: NLM
Urate-Lowering Therapy May Prevent the Development of Coronary Artery Disease in Patients With Gout.

Frontiers in medicine

Yen FS, Hsu CC, Li HL, Wei JC, Hwu CM.
PMID: 32175324
Front Med (Lausanne). 2020 Feb 27;7:63. doi: 10.3389/fmed.2020.00063. eCollection 2020.

Substantial evidence has demonstrated a close relationship between hyperuricemia and cardiovascular (CV) diseases, but few studies have explored the possibility of using urate-lowering therapy (ULT) to attenuate the development of CV diseases. To compare the risks of incident coronary...

Cite
Yen FS, Hsu CC, Li HL, et al. Urate-Lowering Therapy May Prevent the Development of Coronary Artery Disease in Patients With Gout. Front Med (Lausanne). 2020;7:63doi: 10.3389/fmed.2020.00063.
Yen, F. S., Hsu, C. C., Li, H. L., Wei, J. C., & Hwu, C. M. (2020). Urate-Lowering Therapy May Prevent the Development of Coronary Artery Disease in Patients With Gout. Frontiers in medicine, 763. https://doi.org/10.3389/fmed.2020.00063
Yen, Fu-Shun, et al. "Urate-Lowering Therapy May Prevent the Development of Coronary Artery Disease in Patients With Gout." Frontiers in medicine vol. 7 (2020): 63. doi: https://doi.org/10.3389/fmed.2020.00063
Yen FS, Hsu CC, Li HL, Wei JC, Hwu CM. Urate-Lowering Therapy May Prevent the Development of Coronary Artery Disease in Patients With Gout. Front Med (Lausanne). 2020 Feb 27;7:63. doi: 10.3389/fmed.2020.00063. eCollection 2020. PMID: 32175324; PMCID: PMC7056872.
Copy Download .nbib Format: NLM
Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity.

ACS medicinal chemistry letters

Uda J, Kobashi S, Miyata S, Ashizawa N, Matsumoto K, Iwanaga T.
PMID: 33062187
ACS Med Chem Lett. 2020 Jul 15;11(10):2017-2023. doi: 10.1021/acsmedchemlett.0c00176. eCollection 2020 Oct 08.

To derive new uricosuric agents, novel phenol derivatives were synthesized to overcome the disadvantages of benzbromarone (BBR), attributed by its structural features. Herein, we report the discovery of new phenol derivatives with a 1,1-dioxo-1,2-dihydro-3

Cite
Uda J, Kobashi S, Miyata S, et al. Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity. ACS Med Chem Lett. 2020;11(10):2017-2023doi: 10.1021/acsmedchemlett.0c00176.
Uda, J., Kobashi, S., Miyata, S., Ashizawa, N., Matsumoto, K., & Iwanaga, T. (2020). Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity. ACS medicinal chemistry letters, 11(10), 2017-2023. https://doi.org/10.1021/acsmedchemlett.0c00176
Uda, Junichiro, et al. "Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity." ACS medicinal chemistry letters vol. 11,10 (2020): 2017-2023. doi: https://doi.org/10.1021/acsmedchemlett.0c00176
Uda J, Kobashi S, Miyata S, Ashizawa N, Matsumoto K, Iwanaga T. Discovery of Dotinurad (FYU-981), a New Phenol Derivative with Highly Potent Uric Acid Lowering Activity. ACS Med Chem Lett. 2020 Jul 15;11(10):2017-2023. doi: 10.1021/acsmedchemlett.0c00176. eCollection 2020 Oct 08. PMID: 33062187; PMCID: PMC7549256.
Copy Download .nbib Format: NLM
Sex differences in response to allopurinol and benzbromarone in gout: a retrospective cohort study.

Rheumatology advances in practice

Veenstra F, Wanten SAC, Verhoef LM, Ter Stal M, Kwok WY, van den Hoogen FHJ, Flendrie M, van Herwaarden N.
PMID: 33604505
Rheumatol Adv Pract. 2021 Jan 28;5(1):rkab002. doi: 10.1093/rap/rkab002. eCollection 2021.

OBJECTIVE: Owing to lower mean uric acid excretion in women compared with men, uricosuric agents might be preferred in women over xanthine oxidase (XO) inhibitors. We therefore investigated the differences in response to two urate-lowering therapies (ULTs) with different...

Cite
Veenstra F, Wanten SAC, Verhoef LM, et al. Sex differences in response to allopurinol and benzbromarone in gout: a retrospective cohort study. Rheumatol Adv Pract. 2021;5(1):rkab002doi: 10.1093/rap/rkab002.
Veenstra, F., Wanten, S. A. C., Verhoef, L. M., Ter Stal, M., Kwok, W. Y., van den Hoogen, F. H. J., Flendrie, M., & van Herwaarden, N. (2021). Sex differences in response to allopurinol and benzbromarone in gout: a retrospective cohort study. Rheumatology advances in practice, 5(1), rkab002. https://doi.org/10.1093/rap/rkab002
Veenstra, Frouwke, et al. "Sex differences in response to allopurinol and benzbromarone in gout: a retrospective cohort study." Rheumatology advances in practice vol. 5,1 (2021): rkab002. doi: https://doi.org/10.1093/rap/rkab002
Veenstra F, Wanten SAC, Verhoef LM, Ter Stal M, Kwok WY, van den Hoogen FHJ, Flendrie M, van Herwaarden N. Sex differences in response to allopurinol and benzbromarone in gout: a retrospective cohort study. Rheumatol Adv Pract. 2021 Jan 28;5(1):rkab002. doi: 10.1093/rap/rkab002. eCollection 2021. PMID: 33604505; PMCID: PMC7878845.
Copy Download .nbib Format: NLM
Critical appraisal of the role of pegloticase in the management of gout.

Open access rheumatology : research and reviews

Ea HK, Richette P.
PMID: 27790013
Open Access Rheumatol. 2012 Jun 26;4:63-70. doi: 10.2147/OARRR.S17431. eCollection 2012.

Gout is a debilitating disease secondary to chronic hyperuricemia, and the subsequent deposition of monosodium urate crystals is responsible for acute flare, gout arthropathies, tophi and renal lithiasis. Uric acid is the end product of purine metabolism in humans...

Cite
Ea HK, Richette P. Critical appraisal of the role of pegloticase in the management of gout. Open Access Rheumatol. 2012;4:63-70doi: 10.2147/OARRR.S17431.
Ea, H. K., & Richette, P. (2012). Critical appraisal of the role of pegloticase in the management of gout. Open access rheumatology : research and reviews, 463-70. https://doi.org/10.2147/OARRR.S17431
Ea, Hang-Korng, and Richette, Pascal. "Critical appraisal of the role of pegloticase in the management of gout." Open access rheumatology : research and reviews vol. 4 (2012): 63-70. doi: https://doi.org/10.2147/OARRR.S17431
Ea HK, Richette P. Critical appraisal of the role of pegloticase in the management of gout. Open Access Rheumatol. 2012 Jun 26;4:63-70. doi: 10.2147/OARRR.S17431. eCollection 2012. PMID: 27790013; PMCID: PMC5045100.
Copy Download .nbib Format: NLM
Teriflunomide-associated urolithiasis: a new adverse reaction explained by its uricosuric effect.

Fundamental & clinical pharmacology

Largeau B, Béra F, Vannier J, Jonville-Béra AP.
PMID: 33458875
Fundam Clin Pharmacol. 2021 Oct;35(5):930-932. doi: 10.1111/fcp.12647. Epub 2021 Mar 06.

In clinical trials, few investigations have been conducted to determine the mechanism involved in teriflunomide-associated kidney stone formation. We report the first case of recurrent teriflunomide-induced uric acid urolithiasis. A 55-year-old man with relapsing-remitting multiple sclerosis experienced three occurrences...

Cite
Largeau B, Béra F, Vannier J, et al. Teriflunomide-associated urolithiasis: a new adverse reaction explained by its uricosuric effect. Fundam Clin Pharmacol. 2021;35(5):930-932doi: 10.1111/fcp.12647.
Largeau, B., Béra, F., Vannier, J., & Jonville-Béra, A. P. (2021). Teriflunomide-associated urolithiasis: a new adverse reaction explained by its uricosuric effect. Fundamental & clinical pharmacology, 35(5), 930-932. https://doi.org/10.1111/fcp.12647
Largeau, Bérenger, et al. "Teriflunomide-associated urolithiasis: a new adverse reaction explained by its uricosuric effect." Fundamental & clinical pharmacology vol. 35,5 (2021): 930-932. doi: https://doi.org/10.1111/fcp.12647
Largeau B, Béra F, Vannier J, Jonville-Béra AP. Teriflunomide-associated urolithiasis: a new adverse reaction explained by its uricosuric effect. Fundam Clin Pharmacol. 2021 Oct;35(5):930-932. doi: 10.1111/fcp.12647. Epub 2021 Mar 06. PMID: 33458875.
Copy Download .nbib Format: NLM
Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout.

European heart journal

Kang EH, Park EH, Shin A, Song JS, Kim SC.
PMID: 34508567
Eur Heart J. 2021 Nov 21;42(44):4578-4588. doi: 10.1093/eurheartj/ehab619.

AIMS: With the high prevalence of gout and associated cardiovascular (CV) diseases, information on the comparative CV safety of individual urate-lowering drugs becomes increasingly important. However, few studies examined the CV risk of uricosuric agents. We compared CV risk...

Cite
Kang EH, Park EH, Shin A, et al. Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout. Eur Heart J. 2021;42(44):4578-4588doi: 10.1093/eurheartj/ehab619.
Kang, E. H., Park, E. H., Shin, A., Song, J. S., & Kim, S. C. (2021). Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout. European heart journal, 42(44), 4578-4588. https://doi.org/10.1093/eurheartj/ehab619
Kang, Eun Ha, et al. "Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout." European heart journal vol. 42,44 (2021): 4578-4588. doi: https://doi.org/10.1093/eurheartj/ehab619
Kang EH, Park EH, Shin A, Song JS, Kim SC. Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout. Eur Heart J. 2021 Nov 21;42(44):4578-4588. doi: 10.1093/eurheartj/ehab619. PMID: 34508567; PMCID: PMC8633759.
Copy Download .nbib Format: NLM
Metal-Assisted and Microwave-Accelerated Decrystallization: An Alternative Approach to Potential Treatment of Crystal Deposition Diseases.

Clinical archives of bone and joint diseases

Thompson N, Kukoyi ZB, Lansiquot C, Toker S, Kioko B, Ajifa H, Nwawulu C, Daodu O, Aslan K.
PMID: 33834175
Clin Arch Bone Jt Dis. 2017;1(1). doi: 10.23937/cabjd-2017/1710002. Epub 2017 Oct 13.

Gout is a painful and prevalent crystal deposition disease caused by the overproduction of Uric Acid (UA) in the body and the atypical deposition in human synovial joints as Monosodium Urate Monohydrate (MSUM). Conventional treatments, such as NSAIDs, cyclooxygenase-2...

Cite
Thompson N, Kukoyi ZB, Lansiquot C, et al. Metal-Assisted and Microwave-Accelerated Decrystallization: An Alternative Approach to Potential Treatment of Crystal Deposition Diseases. Clin Arch Bone Jt Dis. 2017;1(1)doi: 10.23937/cabjd-2017/1710002.
Thompson, N., Kukoyi, Z. B., Lansiquot, C., Toker, S., Kioko, B., Ajifa, H., Nwawulu, C., Daodu, O., & Aslan, K. (2017). Metal-Assisted and Microwave-Accelerated Decrystallization: An Alternative Approach to Potential Treatment of Crystal Deposition Diseases. Clinical archives of bone and joint diseases, 1(1), . https://doi.org/10.23937/cabjd-2017/1710002
Thompson, Nishone, et al. "Metal-Assisted and Microwave-Accelerated Decrystallization: An Alternative Approach to Potential Treatment of Crystal Deposition Diseases." Clinical archives of bone and joint diseases vol. 1,1 (2017). doi: https://doi.org/10.23937/cabjd-2017/1710002
Thompson N, Kukoyi ZB, Lansiquot C, Toker S, Kioko B, Ajifa H, Nwawulu C, Daodu O, Aslan K. Metal-Assisted and Microwave-Accelerated Decrystallization: An Alternative Approach to Potential Treatment of Crystal Deposition Diseases. Clin Arch Bone Jt Dis. 2017;1(1). doi: 10.23937/cabjd-2017/1710002. Epub 2017 Oct 13. PMID: 33834175; PMCID: PMC8025928.
Copy Download .nbib Format: NLM
The Impact of Urate-Lowering Therapy in Post-Myocardial Infarction Patients: Insights from a Population-Based, Propensity Score-Matched Analysis.

Clinical pharmacology and therapeutics

Tai CJ, Wu CC, Lee KT, Tseng TG, Wang HC, Chang FR, Yang YH.
PMID: 34719019
Clin Pharmacol Ther. 2021 Oct 31; doi: 10.1002/cpt.2473. Epub 2021 Oct 31.

The role of urate-lowering therapy (ULT) for the primary prevention of cardiovascular (CV) events has been widely discussed, but its evidence for the secondary prevention of myocardial infarction (MI) is limited. Therefore, we conduct a population-based, propensity score-matched cohort...

Cite
Tai CJ, Wu CC, Lee KT, et al. The Impact of Urate-Lowering Therapy in Post-Myocardial Infarction Patients: Insights from a Population-Based, Propensity Score-Matched Analysis. Clin Pharmacol Ther. 2021;doi: 10.1002/cpt.2473.
Tai, C. J., Wu, C. C., Lee, K. T., Tseng, T. G., Wang, H. C., Chang, F. R., & Yang, Y. H. (2021). The Impact of Urate-Lowering Therapy in Post-Myocardial Infarction Patients: Insights from a Population-Based, Propensity Score-Matched Analysis. Clinical pharmacology and therapeutics, . https://doi.org/10.1002/cpt.2473
Tai, Chi-Jung, et al. "The Impact of Urate-Lowering Therapy in Post-Myocardial Infarction Patients: Insights from a Population-Based, Propensity Score-Matched Analysis." Clinical pharmacology and therapeutics vol. (2021). doi: https://doi.org/10.1002/cpt.2473
Tai CJ, Wu CC, Lee KT, Tseng TG, Wang HC, Chang FR, Yang YH. The Impact of Urate-Lowering Therapy in Post-Myocardial Infarction Patients: Insights from a Population-Based, Propensity Score-Matched Analysis. Clin Pharmacol Ther. 2021 Oct 31; doi: 10.1002/cpt.2473. Epub 2021 Oct 31. PMID: 34719019.
Copy Download .nbib Format: NLM
Showing 1 to 11 of 11 entries